Compare EPR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | EWTX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 1997 | 2021 |
| Metric | EPR | EWTX |
|---|---|---|
| Price | $59.92 | $46.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $64.14 | $55.42 |
| AVG Volume (30 Days) | 879.5K | ★ 1.6M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.32% | N/A |
| EPS Growth | ★ 105.00 | N/A |
| EPS | 2.75 | ★ 8.86 |
| Revenue | ★ $718,357,000.00 | N/A |
| Revenue This Year | $9.61 | N/A |
| Revenue Next Year | $6.54 | N/A |
| P/E Ratio | $21.53 | ★ $5.19 |
| Revenue Growth | ★ 2.91 | N/A |
| 52 Week Low | $48.36 | $19.76 |
| 52 Week High | $64.97 | $48.78 |
| Indicator | EPR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.86 | 62.79 |
| Support Level | $59.63 | $37.22 |
| Resistance Level | $60.21 | $47.36 |
| Average True Range (ATR) | 1.38 | 3.14 |
| MACD | 0.19 | 0.94 |
| Stochastic Oscillator | 75.00 | 80.22 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.